Toronto, Canada (PRWEB) December 03, 2013
Virus clearance studies are performed to ensure that the purification process has sufficient capability to remove and/or inactivate any viruses that may possibly contaminate the starting material. Selected steps are tested against a panel of viruses, including both enveloped and non-enveloped. It is typically more difficult to show viral clearance for non-enveloped viruses than enveloped viruses because of their smaller size and their relative resistance to physical-chemical inactivation. For these reasons, there is a need for an effective inactivation procedure for non-enveloped viruses.
UV-C treatment has been evaluated in the past for viral inactivation, but recent improvements in the technology have made it practical to use for the first time. Adding this step to a manufacturing process can provide an additional option for viral clearance for products where it is difficult to show adequate clearance. In addition, manufacturers planning to simplify their purification process may find this method beneficial as a means to maintain a sufficient viral clearance level with fewer purification steps.
Join esteemed speakers Dr. Katherine Bergmann, Manager of Viral Safety and Viral Clearance Services at Eurofins Lancaster Laboratories, Dr. Todd Talarico, Vice President of Manufacturing at Medicago, and Sherri Dolan, Field Marketing Manager, Virus Clearance Technologies at Sartorius Stedim North America for this informative session.
During this presentation you will learn:
Copyright©2012 Vocus, Inc.
All rights reserved